ROLE OF COMBINED 18-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY/COMPUTED TOMOGRAPHY IN THE MANAGEMENT OF PATIENTS WITH DIFFERENTIATED THYROID CANCER

Owing to the setting up of new nuclear medicine centers, not only choiceless treatment, such as radioactive iodine therapy, but also an indispensable technique in examination, such as 18-fluorodeoxyglucose positron emission tomography/computed tomography (18FDG PET/CT), has become available to many patients with differentiated thyroid cancer (DTC). The purpose of this review was to analyze numerous studies of new trends in and current recommendations for the use of PET/CT for DTC. Elevated thyroglobulin (TG) levels and negative 131I whole-body scintigraphy data remain a main indication for these techniques. However, PET/CT is also able to change treatment and diagnostic tactics in patients with iodine-sensitive tumors. The minimum TG level, at which it is clinically appropriate to perform PET/CT, has not so far been determined. Whether there is the need for PET/CT during thyroid-stimulating hormone stimulation remains to be solved.

review, differentiated thyroid cancer, combined 18-fluorodeoxyglucose positron emission tomography/ computed tomography, standardized accumulation level, 131I whole-body scintigraphy, thyroglobulin

1. Чиссов В.И., Дарьялова С.Л. Онкология. М.: ГЭОТАР-Медиа; 2007. [Chissov V.I., Dar'yalova S.L. Oncology. Moscow: GEOTARMedia; 2007 (in Russ.).]

2. Sherman S.I. Thyroid carcinoma. Lancet. 2003; 361 (9356): 501–11.

3. Sipos J.A., Mazzaferri E.L. Thyroid cancer epidemiology and prognostic variables. Clinical. Oncology. 2010; 22 (6): 395–404.

4. Eustatia-Rutten C.F., Corssmit E.P., Biermasz N.R., Pereira A.M., Romijn J.A., Smit J.W. Survival and death causes in differentiated thyroid carcinoma. J. Clin. Endocr. Metab. 2006; 91 (1): 313–9.

5. Davies L., Welch H.G. Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 2006; 295 (18): 2164–7.

6. Joensuu H., Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J. Nucl. Med. 1987; 28 (5): 910–4.

7. Feine U., Lietzenmayer R., Hanke J.P., Held J., Wohrle H., Muller-Schauenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J. Nucl. Med. 1996; 37 (9): 1468–72.

8. Salvatori M., Biondi B., Rufini V. 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in differentiatedthyroid carcinoma: clinical indications and controversies in diagnosis and follow-up. Eur. J. Endocr. 2015; 173 (3): 115–30.

9. Padovani R.P., Robenshtok E., Brokhin M., Tuttle R.M. Even without additional therapy, serum thyroglobulin concentrations often decline for years after total thyroidectomy and radioactive remnant ablation in patients with differentiated thyroid cancer. Thyroid. 2012; 22 (8): 778–83.

10. Haugen B.R., Alexander E.K., Bible K.C., Doherty G.M., Mandel S.J., Nikiforov Y.E. et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid. 2016; 26 (1): 1–133.

11. Treglia G., Bertagna F., Piccardo A., Giovanella L. 131-I-whole-body scan or 18-FDG-PET/CT for patients with elevated thyroglobulin and negative ultrasound? Clin. Translat. Imag. 2013; 1 (3): 175–83.

12. Leboulleux S., El Bez I., Borget I., Elleuch M., Deandreis D., Al Ghuzlan A. et al. Post-radioiodine treatment whole body scan in the era of fluorodesoxyglucose positron emission tomography for differentiated thyroid carcinoma with elevated serum thyroglobulin levels. Thyroid. 2012; 22 (8): 832–8.

13. Dong M.J., Liu Z.F., Zhao K., Ruan L.X., Wang G.L., Yang S.Y. et al. Value of 18F-FDG-PET/

14. PET-CT in differentiated thyroid carcinoma with radioiodine-negative whole-body scan. Meta-analysis. Nucl. Med. Commun. 2009; 30 (8): 639–50.

15. Giovanella L. Positron emission tomography/computed tomography in patients treated for differentiated thyroid carcinomas. Expert Rev. Endocr. Metabol. 2012; 7 (1): 35–43.

16. Masson-Deshayes S., Schvartz C., Dalban C., Guendouzen S., Pochart J.M., Dalac A. et al. Prognostic value of (18)F-FDG PET/CT metabolic parameters in metastatic differentiated thyroid cancers. Clin. Nucl. Med. 2015; 40 (6): 469–75.

17. Robbins R.J., Wan Q., Grewal R.K., Reibke R., Gonen M., Strauss H.W. et al. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography scanning. J. Clin. Endocr. Metabol. 2006; 91 (2): 498–505.

18. Deandreis D., Al Ghuzlan A., Leboulleux S. Do histological, immunohistochemical and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome? Endocr. Relat. Cancer. 2011; 18 (1): 159–69.

19. Wang W., Larson S.M., Fazzari M., Tickoo S.K., Kolbert K., Sgouros G. et al. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer. J. Clin. Endocr. Metabol. 2000; 85 (3): 1107–13.

20. Rosenbaum-Krumme S.J., Gorges R., Bockisch A., Binse I. 18F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy. Eur. J. Nucl. Med. Mol. Imag. 2012; 39 (9): 1373–80.

21. Lee J.W., Lee S.M., Lee D.H., Kim Y.J. Clinical utility of 18FFDG PET/CT concurrent with

22. I therapy in intermediate-tohigh-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients. J. Nucl. Med. 2013; 54 (8): 1230–6.

23. Gaertner F.C., Okamoto S., Shiga T., Ito Y.M., Uchiyama Y., Manabe O. et al. FDG PET performed at thyroid remnant ablation has a higher predictive value for longterm survival of high-risk patients with well-differentiated thyroid cancer than radioiodine uptake. Clin. Nucl. Med. 2015; 40 (5): 378–83.

24. Bongiovanni M., Paone G., Ceriani L., Pusztaszeri M. Cellular and molecular basis for thyroid cancer imaging in nuclear medicine. Clin. Translat. Imag. 2013; 1 (3): 149–61.

25. Sisson J.C., Ackermann R.J., Meyer M.A., Wahl R.L. Uptake of 18-fluoro-2-deoxy-D-glucose by thyroid cancer: implications for diagnosis and therapy. J. Clin. Endocr. Metabol. 1993; 77 (4): 1090–4.

26. Chao Ma, Jiawei Xie, Yanhui Lou, Yanyan Gao, Shuyao Zuo, Xufu Wang. The role of TSH for F-FDGPET in the diagnosis of recurrence and metastases of differentiated thyroid carcinoma with elevated thyroglobulin and negative scan: a meta-analysis. Eur. J. Endocr. 2010; 163 (2): 177–83.

27. Charles M., Whitworth P.W., Surasi D.S., Pai S.I., Subramaniam R.M. PET/CT in the management of thyroid cancers. Am. J. Roentgenol. 2014; 202 (6): 1316–29.

28. Bertagna F., Biasiotto G., Orlando E., Bosio G., Giubbini R. Role of 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients affected by differentiated thyroid carcinoma, high thyroglobulin level, and negative 131I scan: review of the literature. Japan. J. Radiol. 2010; 28 (9): 629–36.

29. Schluter B., Bohuslavizki K.H., Beyer W., Plotkin M., Buchert R., Clausen M. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan. J. Nucl. Med. 2001; 42 (1): 71–6.

30. Zimmer L.A., McCook B., Meltzer C., Fukui M., Bascom D., Snyderman C. et al. Combined positron emission tomography/computed tomography imaging of recurrent thyroid cancer. Otolar. Head Neck Surg. 2003; 128 (2): 178–84.

31. Giovanella L., Trimboli P., Verburg F.A., Treglia G., Piccardo A., Foppiani L., Geriani L. Thyroglobulin levels and thyroglobulin doubling time independently predict a positive 18F-FDG PET/CT scan in patients with biochemical recurrence of differentiated thyroid carcinoma. Eur. J. Nucl. Med. Molec. Imag. 2013; 40 (6): 874–80.

32. Shammas A., Degirmenci B., Mountz J.M., McCook B.M., Branstetter B., Bencherif B. et al. 18FFDG PET/CT in patients with suspected recurrent or metastatic well-differentiated thyroid cancer. J. Nucl. Med. 2007; 48 (2): 221–6.